metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
R/R cHL - second line or more (L2) refractory classic Hodgkin lymphoma (R/R cHL) R/R cHL - second line or more (L2)
versus brentuximab vedotin
	pembrolizumab alone vs. brentuximab vedotin	1	-	-387 [-1504; 729] /10000 81/151 vs. 88/153	-